Cargando…

SYTL4 downregulates microtubule stability and confers paclitaxel resistance in triple-negative breast cancer

Background: Taxanes are frontline chemotherapeutic drugs for patients with triple-negative breast cancer (TNBC); however, chemoresistance reduces their effectiveness. We hypothesized that the molecular profiling of tumor samples before and after neoadjuvant chemotherapy (NAC) would help identify gen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xi-Yu, Jiang, Wang, Ma, Ding, Ge, Li-Ping, Yang, Yun-Song, Gou, Zong-Chao, Xu, Xiao-En, Shao, Zhi-Ming, Jiang, Yi-Zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532662/ https://www.ncbi.nlm.nih.gov/pubmed/33042263 http://dx.doi.org/10.7150/thno.45207

Ejemplares similares

SYTL3–SLC22A3 Single-Nucleotide Polymorphisms and Gene–Gene/Environment Interactions on the Risk of Hyperlipidemia
por: Zheng, Peng-Fei, et al.
Publicado: (2021)

High Functioning Autism with Missense Mutations in Synaptotagmin-Like Protein 4 (SYTL4) and Transmembrane Protein 187 (TMEM187) Genes: SYTL4- Protein Modeling, Protein-Protein Interaction, Expression Profiling and MicroRNA Studies
por: Rafi, Syed K., et al.
Publicado: (2019)

Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin
por: Wang, Ruo-Xi, et al.
Publicado: (2016)

SYTL2 promotes metastasis of prostate cancer cells by enhancing FSCN1-mediated pseudopodia formation and invasion
por: Li, Zean, et al.
Publicado: (2023)

A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy
por: Liu, Yuetong, et al.
Publicado: (2023)

Aurora kinase A stabilizes FOXM1 to enhance paclitaxel resistance in triple‐negative breast cancer
por: Yang, Na, et al.
Publicado: (2019)

Transcytosable Peptide-Paclitaxel Prodrug Nanoparticle for Targeted Treatment of Triple-Negative Breast Cancer
por: Wang, Longkun, et al.
Publicado: (2023)

Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer
por: Huang, Liang, et al.
Publicado: (2017)

Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer
por: Liao, Li, et al.
Publicado: (2023)

Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer
por: Lian, Bi, et al.
Publicado: (2020)

MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2
por: Liu, Mei, et al.
Publicado: (2019)

The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel
por: Ahmed, Ahmed Ashour, et al.
Publicado: (2007)

FoxO limits microtubule stability and is itself negatively regulated by microtubule disruption
por: Nechipurenko, Inna V., et al.
Publicado: (2012)

Morphine counteracts the effects of paclitaxel in triple-negative breast cancer cells
por: Sezer, Gülay, et al.
Publicado: (2022)

CDK11 negatively regulates Wnt/β-catenin signaling in the endosomal compartment by affecting microtubule stability
por: Ou, Danmin, et al.
Publicado: (2020)

Transition to lanadelumab‐flyo from three medications for a hereditary angioedema patient with a variant in the SYTL2 gene: A case report
por: Burns, Stephanie, et al.
Publicado: (2021)

Paclitaxel induces Stathmin 1 phosphorylation, microtubule stability and apoptosis in acute lymphoblastic leukemia cells
por: Machado-Neto, João Agostinho, et al.
Publicado: (2017)

Reorganization of paclitaxel-stabilized microtubule arrays at mitotic entry: roles of depolymerizing kinesins and severing proteins
por: Leung, Jessica C., et al.
Publicado: (2019)

Nab-paclitaxel Followed by Dose-dense Epirubicin/Cyclophosphamide in Neoadjuvant Chemotherapy for Triple-negative Breast Cancer: A Phase II Study
por: Liu, Yin, et al.
Publicado: (2022)

Self-Assembly Engineering Nanodrugs Composed of Paclitaxel and Curcumin for the Combined Treatment of Triple Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2021)

LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer
por: Lovat, Francesca, et al.
Publicado: (2013)

Methylseleninic Acid Enhances Paclitaxel Efficacy for the Treatment of Triple-Negative Breast Cancer
por: Qi, Yanfeng, et al.
Publicado: (2012)

Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial
por: Yu, Ke-Da, et al.
Publicado: (2020)

Comprehensive metabolomics expands precision medicine for triple-negative breast cancer
por: Xiao, Yi, et al.
Publicado: (2022)

Photoswitchable paclitaxel-based microtubule stabilisers allow optical control over the microtubule cytoskeleton
por: Müller-Deku, Adrian, et al.
Publicado: (2020)

MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer
por: Wu, Si-Yu, et al.
Publicado: (2021)

Molecular subtypes and precision treatment of triple-negative breast cancer
por: Zhao, Shen, et al.
Publicado: (2020)

BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
por: Blanchard, Zannel, et al.
Publicado: (2015)

Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study
por: Arpino, Grazia, et al.
Publicado: (2015)

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer
por: Sun, Shanshan, et al.
Publicado: (2021)

Co-Delivery of 5-Fluorouracil and Paclitaxel in Mitochondria-Targeted KLA-Modified Liposomes to Improve Triple-Negative Breast Cancer Treatment
por: Chen, Tianyu, et al.
Publicado: (2022)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Effect of SYTL3-SLC22A3 Variants, Their Haplotypes, and G × E Interactions on Serum Lipid Levels and the Risk of Coronary Artery Disease and Ischaemic Stroke
por: Zheng, Peng-Fei, et al.
Publicado: (2021)

Paclitaxel exposure downregulates miR-522 expression and its downregulation induces paclitaxel resistance in ovarian cancer cells
por: Miyamoto, Mayuko, et al.
Publicado: (2020)

GCH1 induces immunosuppression through metabolic reprogramming and IDO1 upregulation in triple-negative breast cancer
por: Wei, Jin-Li, et al.
Publicado: (2021)

Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer
por: Zhou, Yi-Fan, et al.
Publicado: (2021)

Effect of Ect2 Expression on the Growth of Triple-Negative Breast Cancer Cells with Paclitaxel Intervention
por: Wang, Hongkun, et al.
Publicado: (2020)

Molecular Imaging of Oxygenation Changes during Immunotherapy in Combination with Paclitaxel in Triple Negative Breast Cancer
por: Napier, Tiara S., et al.
Publicado: (2023)

Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer
por: Liu, Xi-Yu, et al.
Publicado: (2018)

Sulforaphane metabolites reduce resistance to paclitaxel via microtubule disruption
por: Wang, Yalin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8505tdftcillquh2rumuck6ir1